Charmacy Pharmaceutical Co Ltd
HKEX:2289
EV/GP
Enterprise Value to Gross Profit
Market Cap | EV/GP | ||||
---|---|---|---|---|---|
CN |
C
|
Charmacy Pharmaceutical Co Ltd
HKEX:2289
|
1.5B HKD | 5.5 | |
US |
Mckesson Corp
NYSE:MCK
|
72.5B USD | 5.8 | ||
US |
Cencora Inc
NYSE:COR
|
44.1B USD | 4.9 | ||
US |
Amerisourcebergen Corp
NYSE:ABC
|
35.4B USD | 4.4 | ||
US |
Cardinal Health Inc
NYSE:CAH
|
23.6B USD | 3.3 | ||
US |
Henry Schein Inc
NASDAQ:HSIC
|
9.4B USD | 3 | ||
KR |
C
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 19.4 | |
CN |
Sinopharm Group Co Ltd
HKEX:1099
|
66.9B HKD | 1 | ||
IT |
Amplifon SpA
MIL:AMP
|
7.6B EUR | 15.5 | ||
CN |
Huadong Medicine Co Ltd
SZSE:000963
|
57.5B CNY | 4.4 | ||
CN |
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
52B CNY | 2.4 |
EV/GP Forward Multiples
Forward EV/GP multiple is a version of the EV/GP ratio that uses forecasted gross profit for the EV/GP calculation. 1-Year, 2-Years, and 3-Years forwards use gross profit forecasts for 1, 2, and 3 years ahead, respectively.